Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) in Japanese Adults with Subgenotype 1b Chronic Hepatitis C Virus (HCV) Infection (GIFT I)
Phase 3
- Conditions
- Hepatitis C Virus
- Registration Number
- JPRN-jRCT2080222350
- Lead Sponsor
- AbbVie GK
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Chronic HCV infection prior to study enrollment
- Screening laboratory result indicating HCV subgenotype 1b infection
- Subject has plasma HCV RNA level greater than 10,000 IU/mL at Screening
- Voluntarily sign an informed consent
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method